-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Pharmaceutical Stock Market] Under the catalysis of relevant good news, pharmaceutical stocks have set off a daily limit wave again
.
On January 19, the pharmaceutical sector was still hot.
From the perspective of individual stocks, Aoxiang Pharmaceuticals, Essence Pharmaceuticals, etc.
hit the daily limit today
.
In addition, as of 10:53, Senxuan Pharmaceutical has risen by more than 15%, and Hanyu Pharmaceutical, Guangshengtang, Shanhe Yaofu, etc.
have followed suit
.
It is worth mentioning that under the influence of related concept stocks, Essence Pharmaceuticals has recently recorded 4 daily limits in 5 trading days (January 13-January 18), with a cumulative increase of 56.
49%
.
In the past year, the number of daily limit of the stock has reached 16 times
.
According to the data, Essence Pharmaceutical was established on January 3, 1994.
The company is a company whose main business is the research and development of traditional Chinese patent medicine preparations, chemical raw materials and intermediates, chemical and pharmaceutical intermediates, Chinese herbal medicines and Chinese herbal decoction pieces, biopharmaceuticals, etc.
Production and sales of traditional Chinese medicine enterprises
.
The company's main products are Wang's Baochi Pills, Ji Desheng She Pills, Zheng Chai Hu Yin Granules, Angelica, Bai Shao, Phenobarbital, Fluorouracil, Dioxane, Methyl Hydrazine,
etc.
Since its listing on February 3, 2010, the share price of Essence Pharmaceuticals has risen by 565.
09%
.
Due to the active performance of the stock, the stock has received very high market attention in the past month
.
In fact, after the stock price kept going up and down, Essence Pharmaceuticals issued the "Announcement on Unusual Stock Trading Fluctuations" on December 31, 2021, January 6, 2022, and January 17, 2022, which caused confusion among investors.
Small fluctuations
.
On December 31, 2021, Essence Pharma introduced in the "Announcement on Unusual Fluctuations in Stock Transactions" that the company's stock on December 24, 2021 and December 27, 2021 had a cumulative increase in the deviation value of the closing price for two consecutive trading days.
more than 20%
.
In this regard, the company's board of directors has verified the relevant issues: there is no information disclosed by the company in the previous period that needs to be corrected or supplemented; the company has not found any undisclosed material that may or has had a greater impact on the company's stock trading price recently reported by the public media.
Information; the company, controlling shareholders and actual controllers do not have major events that should be disclosed but not disclosed, or major events in the planning stage; Other violations of fair information disclosure regulations
.
On January 6, 2022, Essence Pharma announced that the company's stock price increased by more than 20% at the closing price on January 4, 2021 and January 5, 2022.
Verification: There is no information disclosed by the company in the early stage that needs to be corrected or supplemented; the company has not found any undisclosed material information recently reported by public media that may or have had a greater impact on the company's stock trading price; the company, controlling shareholders and actual controllers There are no major events about the company that should be disclosed but not disclosed, or major events in the planning stage; during the period of stock change, the company's controlling shareholder did not buy or sell the company's stock; the company did not violate the fair information disclosure regulations
.
On January 17th, Essence Pharma verified the situation that the company's stock's closing price increase on January 13, 2022 and January 14, 2022 had a cumulative deviation of more than 20% of the value of the closing price: the information disclosed by the company in the previous period was not There are points that need to be corrected or supplemented; the company has not found any undisclosed material information recently reported by the public media that may or have had a greater impact on the company's stock trading price; the company, controlling shareholders and actual controllers do not have any information about the company that should be disclosed.
Undisclosed major events, or major events in the planning stage; during the period of stock change, the company's controlling shareholder did not buy or sell the company's stock; the company did not violate the regulations on fair information disclosure
.
However, Essence Pharmaceuticals also stated in the risk warning announcement that the company will strictly comply with the provisions and requirements of relevant laws and regulations, conscientiously perform its information disclosure obligations, and do a good job in information disclosure in a timely manner
.
Investors are requested to invest rationally and pay attention to risks
.
.
On January 19, the pharmaceutical sector was still hot.
From the perspective of individual stocks, Aoxiang Pharmaceuticals, Essence Pharmaceuticals, etc.
hit the daily limit today
.
In addition, as of 10:53, Senxuan Pharmaceutical has risen by more than 15%, and Hanyu Pharmaceutical, Guangshengtang, Shanhe Yaofu, etc.
have followed suit
.
It is worth mentioning that under the influence of related concept stocks, Essence Pharmaceuticals has recently recorded 4 daily limits in 5 trading days (January 13-January 18), with a cumulative increase of 56.
49%
.
In the past year, the number of daily limit of the stock has reached 16 times
.
According to the data, Essence Pharmaceutical was established on January 3, 1994.
The company is a company whose main business is the research and development of traditional Chinese patent medicine preparations, chemical raw materials and intermediates, chemical and pharmaceutical intermediates, Chinese herbal medicines and Chinese herbal decoction pieces, biopharmaceuticals, etc.
Production and sales of traditional Chinese medicine enterprises
.
The company's main products are Wang's Baochi Pills, Ji Desheng She Pills, Zheng Chai Hu Yin Granules, Angelica, Bai Shao, Phenobarbital, Fluorouracil, Dioxane, Methyl Hydrazine,
etc.
Since its listing on February 3, 2010, the share price of Essence Pharmaceuticals has risen by 565.
09%
.
Due to the active performance of the stock, the stock has received very high market attention in the past month
.
In fact, after the stock price kept going up and down, Essence Pharmaceuticals issued the "Announcement on Unusual Stock Trading Fluctuations" on December 31, 2021, January 6, 2022, and January 17, 2022, which caused confusion among investors.
Small fluctuations
.
On December 31, 2021, Essence Pharma introduced in the "Announcement on Unusual Fluctuations in Stock Transactions" that the company's stock on December 24, 2021 and December 27, 2021 had a cumulative increase in the deviation value of the closing price for two consecutive trading days.
more than 20%
.
In this regard, the company's board of directors has verified the relevant issues: there is no information disclosed by the company in the previous period that needs to be corrected or supplemented; the company has not found any undisclosed material that may or has had a greater impact on the company's stock trading price recently reported by the public media.
Information; the company, controlling shareholders and actual controllers do not have major events that should be disclosed but not disclosed, or major events in the planning stage; Other violations of fair information disclosure regulations
.
On January 6, 2022, Essence Pharma announced that the company's stock price increased by more than 20% at the closing price on January 4, 2021 and January 5, 2022.
Verification: There is no information disclosed by the company in the early stage that needs to be corrected or supplemented; the company has not found any undisclosed material information recently reported by public media that may or have had a greater impact on the company's stock trading price; the company, controlling shareholders and actual controllers There are no major events about the company that should be disclosed but not disclosed, or major events in the planning stage; during the period of stock change, the company's controlling shareholder did not buy or sell the company's stock; the company did not violate the fair information disclosure regulations
.
On January 17th, Essence Pharma verified the situation that the company's stock's closing price increase on January 13, 2022 and January 14, 2022 had a cumulative deviation of more than 20% of the value of the closing price: the information disclosed by the company in the previous period was not There are points that need to be corrected or supplemented; the company has not found any undisclosed material information recently reported by the public media that may or have had a greater impact on the company's stock trading price; the company, controlling shareholders and actual controllers do not have any information about the company that should be disclosed.
Undisclosed major events, or major events in the planning stage; during the period of stock change, the company's controlling shareholder did not buy or sell the company's stock; the company did not violate the regulations on fair information disclosure
.
However, Essence Pharmaceuticals also stated in the risk warning announcement that the company will strictly comply with the provisions and requirements of relevant laws and regulations, conscientiously perform its information disclosure obligations, and do a good job in information disclosure in a timely manner
.
Investors are requested to invest rationally and pay attention to risks
.
